Keurig Dr Pepper Inc (KDP) News

Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression

-- Three medical experts will join members of Syros’ leadership team to provide an overview of HR-MDS patient management, perspectives on the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update

– Passed Interim Futility Analysis of the Primary Endpoint in Phase 3 SELECT-MDS-1 Trial of Tamibarotene; Pivotal CR Data Expected by Mid-4Q...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Syros to Participate in Upcoming Investor Conferences

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of...

Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of...

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of...

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of...

Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

-- Completed Enrollment of 190 Patients for Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial; Pivotal CR Data Expected by Mid-4Q 2024...

U.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early Trading

U.S. index futures indicate an uptrend in pre-market trading on Wednesday, bouncing back after a previous...

Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial

-- On track to report pivotal complete response data by mid-4Q 2024 -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed...

Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of...

Syros to Participate in TD Cowen 44th Annual Health Care Conference

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of...